These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36044257)

  • 1. The Discovery of GSK3640254, a Next-Generation Inhibitor of HIV-1 Maturation.
    Regueiro-Ren A; Sit SY; Chen Y; Chen J; Swidorski JJ; Liu Z; Venables BL; Sin N; Hartz RA; Protack T; Lin Z; Zhang S; Li Z; Wu DR; Li P; Kempson J; Hou X; Gupta A; Rampulla R; Mathur A; Park H; Sarjeant A; Benitex Y; Rahematpura S; Parker D; Phillips T; Haskell R; Jenkins S; Santone KS; Cockett M; Hanumegowda U; Dicker I; Meanwell NA; Krystal M
    J Med Chem; 2022 Sep; 65(18):11927-11948. PubMed ID: 36044257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and exploration of C-3 benzoic acid bioisosteres and alkyl replacements in the context of GSK3532795 (BMS-955176) that exhibit broad spectrum HIV-1 maturation inhibition.
    Swidorski JJ; Jenkins S; Hanumegowda U; Parker DD; Beno BR; Protack T; Ng A; Gupta A; Shanmugam Y; Dicker IB; Krystal M; Meanwell NA; Regueiro-Ren A
    Bioorg Med Chem Lett; 2021 Mar; 36():127823. PubMed ID: 33508465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis, and SAR of C-3 Benzoic Acid, C-17 Triterpenoid Derivatives. Identification of the HIV-1 Maturation Inhibitor 4-((1 R,3a S,5a R,5b R,7a R,11a S,11b R,13a R,13b R)-3a-((2-(1,1-Dioxidothiomorpholino)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1 H-cyclopenta[ a]chrysen-9-yl)benzoic Acid (GSK3532795, BMS-955176).
    Regueiro-Ren A; Swidorski JJ; Liu Z; Chen Y; Sin N; Sit SY; Chen J; Venables BL; Zhu J; Nowicka-Sans B; Protack T; Lin Z; Terry B; Samanta H; Zhang S; Li Z; Easter J; Beno BR; Arora V; Huang XS; Rahematpura S; Parker DD; Haskell R; Santone KS; Cockett MI; Krystal M; Meanwell NA; Jenkins S; Hanumegowda U; Dicker IB
    J Med Chem; 2018 Aug; 61(16):7289-7313. PubMed ID: 30067361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next-generation HIV-1 maturation inhibitor.
    Joshi SR; Fernando D; Igwe S; McKenzie L; Krishnatry AS; Halliday F; Zhan J; Greene TJ; Xu J; Ferron-Brady G; Lataillade M; Min S
    Pharmacol Res Perspect; 2020 Dec; 8(6):e00671. PubMed ID: 33200887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of HIV-1 maturation: Development of structure-activity relationship for C-28 amides based on C-3 benzoic acid-modified triterpenoids.
    Swidorski JJ; Liu Z; Sit SY; Chen J; Chen Y; Sin N; Venables BL; Parker DD; Nowicka-Sans B; Terry BJ; Protack T; Rahematpura S; Hanumegowda U; Jenkins S; Krystal M; Dicker IB; Meanwell NA; Regueiro-Ren A
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1925-30. PubMed ID: 26988305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-3 benzoic acid derivatives of C-3 deoxybetulinic acid and deoxybetulin as HIV-1 maturation inhibitors.
    Liu Z; Swidorski JJ; Nowicka-Sans B; Terry B; Protack T; Lin Z; Samanta H; Zhang S; Li Z; Parker DD; Rahematpura S; Jenkins S; Beno BR; Krystal M; Meanwell NA; Dicker IB; Regueiro-Ren A
    Bioorg Med Chem; 2016 Apr; 24(8):1757-70. PubMed ID: 26968652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The design, synthesis and structure-activity relationships associated with C28 amine-based betulinic acid derivatives as inhibitors of HIV-1 maturation.
    Chen Y; Sit SY; Chen J; Swidorski JJ; Liu Z; Sin N; Venables BL; Parker DD; Nowicka-Sans B; Lin Z; Li Z; Terry BJ; Protack T; Rahematpura S; Hanumegowda U; Jenkins S; Krystal M; Dicker ID; Meanwell NA; Regueiro-Ren A
    Bioorg Med Chem Lett; 2018 May; 28(9):1550-1557. PubMed ID: 29631960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage.
    Nowicka-Sans B; Protack T; Lin Z; Li Z; Zhang S; Sun Y; Samanta H; Terry B; Liu Z; Chen Y; Sin N; Sit SY; Swidorski JJ; Chen J; Venables BL; Healy M; Meanwell NA; Cockett M; Hanumegowda U; Regueiro-Ren A; Krystal M; Dicker IB
    Antimicrob Agents Chemother; 2016 Jul; 60(7):3956-69. PubMed ID: 27090171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants.
    Pene Dumitrescu T; Joshi SR; Xu J; Zhan J; Johnson M; Butcher L; Zimmerman E; Webster L; Davidson AM; Lataillade M; Min S
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33753329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial.
    Morales-Ramirez J; Bogner JR; Molina JM; Lombaard J; Dicker IB; Stock DA; DeGrosky M; Gartland M; Pene Dumitrescu T; Min S; Llamoso C; Joshi SR; Lataillade M
    PLoS One; 2018; 13(10):e0205368. PubMed ID: 30352054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GSK3640254 Is a Novel HIV-1 Maturation Inhibitor with an Optimized Virology Profile.
    Dicker I; Jeffrey JL; Protack T; Lin Z; Cockett M; Chen Y; Sit SY; Gartland M; Meanwell NA; Regueiro-Ren A; Drexler D; Cantone J; McAuliffe B; Krystal M
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0187621. PubMed ID: 34780263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of the HIV-1 Maturation Inhibitor GSK3640254 Using an Intravenous Microtracer Combined with EnteroTracker for Biliary Sampling.
    Wen B; Zhang Y; Young GC; Kenworthy D; Pereira A; Pirhalla J; Doyle J; Jordon B; Zhan J; Johnson M
    Drug Metab Dispos; 2022 Nov; 50(11):1442-1453. PubMed ID: 36153007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I evaluation of pharmacokinetics and tolerability of the HIV-1 maturation inhibitor GSK3640254 and dolutegravir in healthy adults.
    Pene Dumitrescu T; Joshi SR; Xu J; Greene TJ; Johnson M; Butcher L; Zimmerman E; Webster L; Pham TT; Lataillade M; Min S
    Br J Clin Pharmacol; 2021 Sep; 87(9):3501-3507. PubMed ID: 33533507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of pharmacokinetic interaction between the HIV-1 maturation inhibitor GSK3640254 and combination oral contraceptives in healthy women.
    Pene Dumitrescu T; Greene TJ; Joshi SR; Xu J; Johnson M; Halliday F; Butcher L; Zimmerman E; Webster L; Pham TT; Lataillade M; Min S
    Br J Clin Pharmacol; 2022 Feb; 88(4):1704-1712. PubMed ID: 34427938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors.
    Lin Z; Cantone J; Lu H; Nowicka-Sans B; Protack T; Yuan T; Yang H; Liu Z; Drexler D; Regueiro-Ren A; Meanwell NA; Cockett M; Krystal M; Lataillade M; Dicker IB
    PLoS Pathog; 2016 Nov; 12(11):e1005990. PubMed ID: 27893830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-AIDS agents 81. Design, synthesis, and structure-activity relationship study of betulinic acid and moronic acid derivatives as potent HIV maturation inhibitors.
    Qian K; Kuo RY; Chen CH; Huang L; Morris-Natschke SL; Lee KH
    J Med Chem; 2010 Apr; 53(8):3133-41. PubMed ID: 20329730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, Structure-Activity Relationships, and
    Hartz RA; Xu L; Sit SY; Chen J; Venables BL; Lin Z; Zhang S; Li Z; Parker D; Simmons TS; Jenkins S; Hanumegowda UM; Dicker I; Krystal M; Meanwell NA; Regueiro-Ren A
    J Med Chem; 2022 Dec; 65(23):15935-15966. PubMed ID: 36441509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative Bioavailability and Food Effect of GSK3640254 Tablet and Capsule Formulations in Healthy Participants.
    Johnson M; Pene Dumitrescu T; Joshi SR; Mathew A; Bainbridge V; Zhan J; Lataillade M
    Clin Pharmacol Drug Dev; 2022 May; 11(5):632-639. PubMed ID: 34995417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a novel and potent class of anti-HIV-1 maturation inhibitors with improved virology profile against gag polymorphisms.
    Tang J; Jones SA; Jeffrey JL; Miranda SR; Galardi CM; Irlbeck DM; Brown KW; McDanal CB; Johns BA
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2689-2694. PubMed ID: 28454672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254.
    Spinner CD; Felizarta F; Rizzardini G; Philibert P; Mitha E; Domingo P; Stephan CJ; DeGrosky M; Bainbridge V; Zhan J; Dumitrescu TP; Jeffrey JL; Xu J; Halliday F; Gan J; Johnson M; Gartland M; Joshi SR; Lataillade M
    Clin Infect Dis; 2022 Sep; 75(5):786-794. PubMed ID: 34996113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.